Ideas in this flowchart

• Phase 2b trial comparing T+D+CT with P+CT in patients
• The trial randomly assigned 84 patients: 41 to T+D+CT and 43 to P+CT.
• T+D+CT arm: 41 patients
• Patients received 75 mg tremelimumab, 1500 mg durvalumab, and pemetrexed-platinum chemotherapy every 3 weeks for 4 cycles.
• Maintenance treatment consisted of durvalumab and pemetrexed every 4 weeks until disease progression, with additional tremelimumab at week 16 and optionally at month 24.
• P+CT arm: 43 patients
• Patients received 200 mg pembrolizumab plus chemotherapy every 3 weeks until disease progression, for up to 24 months.
• Confirmed objective response rate was 39.0% with T+D+CT and 34.9% with P+CT.
• Median duration of response was not reached with T+D+CT and was 6.4 months with P+CT.
• At 6 months, 100% of responders in the T+D+CT arm remained in response, compared with 58.3% in the P+CT arm.
• The reported findings came from the presentation abstract for trial NCT06008093.